25 XP   0   0   10

Virpax Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Virpax Pharmaceuticals Inc together

PenkeI guess you are interested in Virpax Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Virpax Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Virpax Pharmaceuticals Inc

I send you an email if I find something interesting about Virpax Pharmaceuticals Inc.

Quick analysis of Virpax Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Virpax Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.65
Expected worth in 1 year
$-10.85
How sure are you?
17.6%

+ What do you gain per year?

Total Gains per Share
$-12.50
Return On Investment
-395.6%

For what price can you sell your share?

Current Price per Share
$3.16
Expected price per share
$2.4 - $5.48
How sure are you?
50%

1. Valuation of Virpax Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$3.16

Intrinsic Value Per Share

$-152.82 - $-182.11

Total Value Per Share

$-151.17 - $-180.46

2. Growth of Virpax Pharmaceuticals Inc (5 min.)




Is Virpax Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1.9m$23.8m-$14.8m-165.7%

How much money is Virpax Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.7m-$5.3m$1.5m42.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Virpax Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#812 / 1010

Most Revenue
#823 / 1010

Most Profit
#379 / 1010

Most Efficient
#263 / 1010

What can you expect buying and holding a share of Virpax Pharmaceuticals Inc? (5 min.)

Welcome investor! Virpax Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Virpax Pharmaceuticals Inc.

What can you expect buying and holding a share of Virpax Pharmaceuticals Inc?

First you should know what it really means to hold a share of Virpax Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Virpax Pharmaceuticals Inc is $3.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Virpax Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Virpax Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.65. Based on the TTM, the Book Value Change Per Share is $-3.13 per quarter. Based on the YOY, the Book Value Change Per Share is $2.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Virpax Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.89-123.3%-3.21-101.7%-1.01-32.0%-1.18-37.5%-1.18-37.5%
Usd Book Value Change Per Share-3.90-123.5%-3.13-98.9%2.1367.6%0.103.1%0.103.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-3.90-123.5%-3.13-98.9%2.1367.6%0.103.1%0.103.1%
Usd Price Per Share0.32-0.75-1.43-1.54-1.54-
Price to Earnings Ratio-0.02--0.08--0.66--0.64--0.64-
Price-to-Total Gains Ratio-0.08--0.34--1.52--1.07--1.07-
Price to Book Ratio0.19-0.13-0.57-0.53-0.53-
Price-to-Total Gains Ratio-0.08--0.34--1.52--1.07--1.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.16
Number of shares316
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-3.130.10
Usd Total Gains Per Share-3.130.10
Gains per Quarter (316 shares)-987.6130.70
Gains per Year (316 shares)-3,950.42122.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3950-39600123113
20-7901-79100246236
30-11851-118600368359
40-15802-158100491482
50-19752-197600614605
60-23703-237100737728
70-27653-276600860851
80-31603-316100982974
90-35554-35560011051097
100-39504-39510012281220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%3.012.02.017.6%3.012.02.017.6%3.012.02.017.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%3.012.02.017.6%3.012.02.017.6%3.012.02.017.6%

Fundamentals of Virpax Pharmaceuticals Inc

About Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Fundamental data was last updated by Penke on 2024-04-12 21:47:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Virpax Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Virpax Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Virpax Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • -47.4% Return on Assets means that Virpax Pharmaceuticals Inc generated $-0.47 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Virpax Pharmaceuticals Inc:

  • The MRQ is -47.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-47.4%TTM-30.1%-17.3%
TTM-30.1%YOY-20.3%-9.7%
TTM-30.1%5Y-377.1%+347.0%
5Y-377.1%10Y-377.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-47.4%-13.3%-34.1%
TTM-30.1%-12.8%-17.3%
YOY-20.3%-11.7%-8.6%
5Y-377.1%-13.9%-363.2%
10Y-377.1%-15.7%-361.4%
1.1.3. Return on Equity

Shows how efficient Virpax Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • -235.8% Return on Equity means Virpax Pharmaceuticals Inc generated $-2.36 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Virpax Pharmaceuticals Inc:

  • The MRQ is -235.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -90.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-235.8%TTM-90.6%-145.2%
TTM-90.6%YOY-23.5%-67.1%
TTM-90.6%5Y-31.2%-59.4%
5Y-31.2%10Y-31.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-235.8%-16.9%-218.9%
TTM-90.6%-16.1%-74.5%
YOY-23.5%-15.1%-8.4%
5Y-31.2%-19.3%-11.9%
10Y-31.2%-20.2%-11.0%

1.2. Operating Efficiency of Virpax Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Virpax Pharmaceuticals Inc is operating .

  • Measures how much profit Virpax Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y--632.4%+632.4%
1.2.2. Operating Ratio

Measures how efficient Virpax Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y-7.876-7.876

1.3. Liquidity of Virpax Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Virpax Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.25 means the company has $1.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 1.251. The company is just able to pay all its short-term debts.
  • The TTM is 3.309. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.251TTM3.309-2.057
TTM3.309YOY9.926-6.617
TTM3.3095Y6.200-2.891
5Y6.20010Y6.2000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2513.890-2.639
TTM3.3094.173-0.864
YOY9.9265.344+4.582
5Y6.2006.126+0.074
10Y6.2006.448-0.248
1.3.2. Quick Ratio

Measures if Virpax Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.19 means the company can pay off $1.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 1.188. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 3.066. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.188TTM3.066-1.878
TTM3.066YOY8.900-5.834
TTM3.0665Y5.718-2.652
5Y5.71810Y5.7180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1883.514-2.326
TTM3.0663.998-0.932
YOY8.9005.380+3.520
5Y5.7186.105-0.387
10Y5.7186.404-0.686

1.4. Solvency of Virpax Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Virpax Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Virpax Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.80 means that Virpax Pharmaceuticals Inc assets are financed with 79.9% credit (debt) and the remaining percentage (100% - 79.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.799. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.427. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.799TTM0.427+0.372
TTM0.427YOY0.121+0.306
TTM0.4275Y11.820-11.393
5Y11.82010Y11.8200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7990.339+0.460
TTM0.4270.336+0.091
YOY0.1210.271-0.150
5Y11.8200.366+11.454
10Y11.8200.389+11.431
1.4.2. Debt to Equity Ratio

Measures if Virpax Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 397.8% means that company has $3.98 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 3.978. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.374. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ3.978TTM1.374+2.604
TTM1.374YOY0.141+1.233
TTM1.3745Y0.415+0.959
5Y0.41510Y0.4150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9780.388+3.590
TTM1.3740.402+0.972
YOY0.1410.335-0.194
5Y0.4150.426-0.011
10Y0.4150.461-0.046

2. Market Valuation of Virpax Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Virpax Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Virpax Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.02 means the investor is paying $-0.02 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Virpax Pharmaceuticals Inc:

  • The EOD is -0.203. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.021. Based on the earnings, the company is expensive. -2
  • The TTM is -0.082. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.203MRQ-0.021-0.182
MRQ-0.021TTM-0.082+0.061
TTM-0.082YOY-0.655+0.573
TTM-0.0825Y-0.644+0.562
5Y-0.64410Y-0.6440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.203-2.264+2.061
MRQ-0.021-2.629+2.608
TTM-0.082-2.680+2.598
YOY-0.655-4.145+3.490
5Y-0.644-6.257+5.613
10Y-0.644-6.254+5.610
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Virpax Pharmaceuticals Inc:

  • The EOD is -0.307. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.031. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.095. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.307MRQ-0.031-0.276
MRQ-0.031TTM-0.095+0.064
TTM-0.095YOY-0.716+0.621
TTM-0.0955Y-0.622+0.527
5Y-0.62210Y-0.6220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.307-2.973+2.666
MRQ-0.031-3.333+3.302
TTM-0.095-3.553+3.458
YOY-0.716-5.605+4.889
5Y-0.622-8.376+7.754
10Y-0.622-8.865+8.243
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Virpax Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.19 means the investor is paying $0.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Virpax Pharmaceuticals Inc:

  • The EOD is 1.913. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.194. Based on the equity, the company is cheap. +2
  • The TTM is 0.125. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.913MRQ0.194+1.720
MRQ0.194TTM0.125+0.068
TTM0.125YOY0.573-0.447
TTM0.1255Y0.532-0.406
5Y0.53210Y0.5320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9131.896+0.017
MRQ0.1942.115-1.921
TTM0.1252.093-1.968
YOY0.5732.884-2.311
5Y0.5323.542-3.010
10Y0.5323.916-3.384
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Virpax Pharmaceuticals Inc.

3.1. Institutions holding Virpax Pharmaceuticals Inc

Institutions are holding 3.258% of the shares of Virpax Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31PNC Financial Services Group Inc0.8611010087500
2023-12-31Vanguard Group Inc0.565906629411491.7638
2023-12-31Geode Capital Management, LLC0.545706392800
2023-12-31Sheets Smith Wealth Management0.42680.002350000500000
2023-12-31Renaissance Technologies Corp0.2604030500-40600-57.1027
2023-12-31Susquehanna International Group, LLP0.1514017734177340
2023-12-31Northern Trust Corp0.129901522100
2023-12-31TWO SIGMA SECURITIES, LLC0.0998011695116950
2023-12-31UBS Group AG0.05650661664985506.7797
2023-12-31Tower Research Capital LLC0.053906318981.5756
2023-12-31JPMorgan Chase & Co0.03720435843580
2023-12-31Advisor Group Holdings, Inc.0.0205024001800300
2023-12-31Signature Resources Capital Management, LLC0.00430.00025005000
2023-12-31BlackRock Inc0.004046400
2023-12-31Morgan Stanley - Brokerage Accounts0.0013015000
2023-12-31Wells Fargo & Co0.000606746.3492
2023-12-31Parallel Advisors, LLC0.0001014140
2023-12-31Sabby Management LLC000-292790-100
Total 3.21940.0025377134-239540-63.5%

3.2. Funds holding Virpax Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.565906629400
2024-01-31Fidelity Extended Market Index0.373304373200
2024-01-31Fidelity Series Total Market Index0.089201044500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0810.0001949000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06510.00017622140.184
2024-01-31Fidelity Nasdaq Composite Index0.05480641900
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04890573100
2023-12-31Northern Trust Extended Eq Market Idx0.04890573100
2024-01-31Spartan Total Market Index Pool E0.02740321000
2024-02-29State St US Extended Mkt Indx NL Cl C0.006070000
2023-12-31SSgA U.S. Extended Market Index Class I0.006070000
2023-09-30BlackRock Extended Mkt Composite0.004046400
2023-12-31BlackRock Extended Equity Market K0.00350405-1-0.2463
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00260.000130710.3268
2023-12-31SSgA U.S. Total Market Index Strategy0.00170202-5-2.4155
2023-12-31Extended Equity Market Fund M0.000405024.1667
Total 1.37870.0003161502+11+0.0%

3.3. Insider Transactions

Insiders are holding 25.722% of the shares of Virpax Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-24Jerrold SendrowBUY45012.9
2022-05-18Anthony P MackBUY757513.4
2022-05-18Eric FloydBUY44713.6
2021-11-22Jerrold SendrowBUY39039.2
2021-11-18Anthony P MackBUY251239.9

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Virpax Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.902-3.125-20%2.135-283%0.097-4117%0.097-4117%
Book Value Per Share--1.6527.671-78%5.223-68%3.799-57%3.799-57%
Current Ratio--1.2513.309-62%9.926-87%6.200-80%6.200-80%
Debt To Asset Ratio--0.7990.427+87%0.121+562%11.820-93%11.820-93%
Debt To Equity Ratio--3.9781.374+190%0.141+2728%0.415+859%0.415+859%
Dividend Per Share----0%-0%-0%-0%
Eps---3.895-3.214-17%-1.011-74%-1.184-70%-1.184-70%
Free Cash Flow Per Share---2.571-2.103-18%-0.682-73%-0.833-68%-0.833-68%
Free Cash Flow To Equity Per Share---2.571-2.103-18%-0.682-73%-0.051-98%-0.051-98%
Gross Profit Margin--1.2741.069+19%1.000+27%1.016+25%1.016+25%
Intrinsic Value_10Y_max---182.109--------
Intrinsic Value_10Y_min---152.819--------
Intrinsic Value_1Y_max---6.588--------
Intrinsic Value_1Y_min---6.464--------
Intrinsic Value_3Y_max---28.680--------
Intrinsic Value_3Y_min---27.201--------
Intrinsic Value_5Y_max---61.487--------
Intrinsic Value_5Y_min---56.306--------
Market Cap3701086.800+90%374794.560874162.545-57%15084566.517-98%9219981.921-96%9219981.921-96%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.913+90%0.1940.125+55%0.573-66%0.532-64%0.532-64%
Pe Ratio-0.203-888%-0.021-0.082+298%-0.655+3089%-0.644+3033%-0.644+3033%
Price Per Share3.160+90%0.3200.746-57%1.428-78%1.540-79%1.540-79%
Price To Free Cash Flow Ratio-0.307-888%-0.031-0.095+204%-0.716+2201%-0.622+1899%-0.622+1899%
Price To Total Gains Ratio-0.810-888%-0.082-0.337+311%-1.519+1752%-1.070+1205%-1.070+1205%
Quick Ratio--1.1883.066-61%8.900-87%5.718-79%5.718-79%
Return On Assets---0.474-0.301-36%-0.203-57%-3.771+696%-3.771+696%
Return On Equity---2.358-0.906-62%-0.235-90%-0.312-87%-0.312-87%
Total Gains Per Share---3.902-3.125-20%2.135-283%0.097-4117%0.097-4117%
Usd Book Value--1934321.0008985922.750-78%23871276.750-92%12424050.765-84%12424050.765-84%
Usd Book Value Change Per Share---3.902-3.125-20%2.135-283%0.097-4117%0.097-4117%
Usd Book Value Per Share--1.6527.671-78%5.223-68%3.799-57%3.799-57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---3.895-3.214-17%-1.011-74%-1.184-70%-1.184-70%
Usd Free Cash Flow---3011481.000-2463443.000-18%-4461677.000+48%-2582010.941-14%-2582010.941-14%
Usd Free Cash Flow Per Share---2.571-2.103-18%-0.682-73%-0.833-68%-0.833-68%
Usd Free Cash Flow To Equity Per Share---2.571-2.103-18%-0.682-73%-0.051-98%-0.051-98%
Usd Market Cap3701086.800+90%374794.560874162.545-57%15084566.517-98%9219981.921-96%9219981.921-96%
Usd Price Per Share3.160+90%0.3200.746-57%1.428-78%1.540-79%1.540-79%
Usd Profit---4561709.000-3764744.250-17%-5364076.750+18%-3153589.000-31%-3153589.000-31%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---3.902-3.125-20%2.135-283%0.097-4117%0.097-4117%
 EOD+5 -3MRQTTM+3 -27YOY+6 -245Y+6 -2410Y+6 -24

4.2. Fundamental Score

Let's check the fundamental score of Virpax Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.203
Price to Book Ratio (EOD)Between0-11.913
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.188
Current Ratio (MRQ)Greater than11.251
Debt to Asset Ratio (MRQ)Less than10.799
Debt to Equity Ratio (MRQ)Less than13.978
Return on Equity (MRQ)Greater than0.15-2.358
Return on Assets (MRQ)Greater than0.05-0.474
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Virpax Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.983
Ma 20Greater thanMa 503.758
Ma 50Greater thanMa 1003.740
Ma 100Greater thanMa 2003.583
OpenGreater thanClose3.220
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets9,628
Total Liabilities7,694
Total Stockholder Equity1,934
 As reported
Total Liabilities 7,694
Total Stockholder Equity+ 1,934
Total Assets = 9,628

Assets

Total Assets9,628
Total Current Assets9,628
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 9,142
Other Current Assets 487
Total Current Assets  (as reported)9,628
Total Current Assets  (calculated)9,628
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,694
Long-term Liabilities0
Total Stockholder Equity1,934
Total Current Liabilities
Other Current Liabilities 7,694
Total Current Liabilities  (as reported)7,694
Total Current Liabilities  (calculated)7,694
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -59,544
Other Stockholders Equity 61,478
Total Stockholder Equity (as reported)1,934
Total Stockholder Equity (calculated)1,934
+/-0
Other
Capital Stock0
Cash and Short Term Investments 9,142
Common Stock Shares Outstanding 1,171
Liabilities and Stockholders Equity 9,628
Net Debt -9,142
Net Invested Capital 1,934
Net Working Capital 1,934



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
47
0
0
451
465
13,219
11,388
43,273
39,572
34,746
29,402
23,636
19,674
18,493
15,951
13,038
9,628
9,62813,03815,95118,49319,67423,63629,40234,74639,57243,27311,38813,2194654510047
   > Total Current Assets 
47
825
825
275
73
13,219
11,388
43,273
39,572
34,746
29,402
23,636
19,674
18,493
15,951
13,038
9,628
9,62813,03815,95118,49319,67423,63629,40234,74639,57243,27311,38813,2197327582582547
       Cash And Cash Equivalents 
42
0
0
257
55
12,264
10,467
41,713
36,842
30,797
26,061
20,563
18,995
16,987
14,804
12,153
9,142
9,14212,15314,80416,98718,99520,56326,06130,79736,84241,71310,46712,264552570042
       Net Receivables 
1
375
375
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000003753751
       Inventory 
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003
       Other Current Assets 
0
8
8
3
1
955
6
1,101
2,466
2,795
2,583
2,593
522
1,506
1,147
885
487
4878851,1471,5065222,5932,5832,7952,4661,101695513880
   > Long-term Assets 
0
0
0
176
392
0
0
0
0
0
0
0
0
0
0
0
0
000000000000392176000
       Other Assets 
0
73
73
176
392
0
0
0
0
0
0
0
0
0
0
0
0
00000000000039217673730
> Total Liabilities 
2,779
0
0
4,297
4,682
3,662
3,852
1,812
2,088
2,187
2,483
4,208
3,095
3,294
3,647
6,533
7,694
7,6946,5333,6473,2943,0954,2082,4832,1872,0881,8123,8523,6624,6824,297002,779
   > Total Current Liabilities 
2,779
3,540
3,540
3,267
3,660
2,640
2,830
1,812
2,088
2,187
2,483
4,208
3,095
3,294
3,647
6,533
7,694
7,6946,5333,6473,2943,0954,2082,4832,1872,0881,8122,8302,6403,6603,2673,5403,5402,779
       Short-term Debt 
1,265
0
0
536
544
51
51
0
0
0
0
0
0
0
0
0
0
00000000005151544536001,265
       Short Long Term Debt 
1,265
0
0
536
544
51
51
0
0
0
0
0
0
0
0
0
0
00000000005151544536001,265
       Accounts payable 
3
18
18
7
3,116
5
2,780
1,812
8
2,187
2,483
4,208
1,095
0
0
0
0
00001,0954,2082,4832,18781,8122,78053,116718183
       Other Current Liabilities 
1,514
0
0
2,732
3,116
2,590
2,780
1,812
2,088
2,187
2,483
4,208
2,000
3,294
3,647
6,533
7,694
7,6946,5333,6473,2942,0004,2082,4832,1872,0881,8122,7802,5903,1162,732001,514
   > Long-term Liabilities 
1,265
0
0
1,030
1,022
1,022
1,022
0
0
0
2,483
4,208
1,095
0
0
0
0
00001,0954,2082,4830001,0221,0221,0221,030001,265
       Deferred Long Term Liability 
0
73
73
176
392
0
0
0
0
0
0
0
0
0
0
0
0
00000000000039217673730
> Total Stockholder Equity
-2,732
0
0
-3,846
-4,216
9,558
7,536
41,461
37,485
32,559
26,919
19,428
16,579
15,199
12,305
6,506
1,934
1,9346,50612,30515,19916,57919,42826,91932,55937,48541,4617,5369,558-4,216-3,84600-2,732
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000
   Retained Earnings -59,544-54,982-48,988-45,875-44,355-41,368-33,726-27,841-22,704-18,586-15,371-13,027-10,648-9,943-8,234-8,234-6,308
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
3,576
0
0
6,096
6,432
22,585
22,906
60,047
60,189
60,400
60,645
60,795
60,934
61,074
61,292
61,488
61,478
61,47861,48861,29261,07460,93460,79560,64560,40060,18960,04722,90622,5856,4326,096003,576



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-16,940
Operating Income-16,940-16,940
 
Operating Expense (+$)
Research Development5,118
Selling General Administrative10,572,181
Selling And Marketing Expenses10,560,359
Operating Expense16,94021,137,657
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-16,940
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-15,190-18,690
EBIT - interestExpense = 0
-15,190
-15,190
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-15,190
Earnings Before Interest and Taxes (EBITDA)-16,940
 
After tax Income (+$)
Income Before Tax-15,190
Tax Provision-0
Net Income From Continuing Ops-13,615-15,190
Net Income-15,190
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,940
Total Other Income/Expenses Net1,7500
 

Technical Analysis of Virpax Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Virpax Pharmaceuticals Inc. The general trend of Virpax Pharmaceuticals Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Virpax Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Virpax Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.25 < 4.825 < 5.48.

The bearish price targets are: 2.64 > 2.54 > 2.4.

Tweet this
Virpax Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Virpax Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Virpax Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Virpax Pharmaceuticals Inc. The current macd is -0.12198269.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Virpax Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Virpax Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Virpax Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Virpax Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartVirpax Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Virpax Pharmaceuticals Inc. The current adx is 16.46.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Virpax Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Virpax Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Virpax Pharmaceuticals Inc. The current sar is 4.36623386.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Virpax Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Virpax Pharmaceuticals Inc. The current rsi is 39.98. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Virpax Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartVirpax Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Virpax Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Virpax Pharmaceuticals Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Virpax Pharmaceuticals Inc Daily Stochastic Oscillator ChartVirpax Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Virpax Pharmaceuticals Inc. The current cci is -160.24445804.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Virpax Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartVirpax Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Virpax Pharmaceuticals Inc. The current cmo is -29.46695133.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Virpax Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartVirpax Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Virpax Pharmaceuticals Inc. The current willr is -87.60072784.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Virpax Pharmaceuticals Inc Daily Williams %R ChartVirpax Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Virpax Pharmaceuticals Inc. The current atr is 0.39321147.

Virpax Pharmaceuticals Inc Daily Average True Range (ATR) ChartVirpax Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Virpax Pharmaceuticals Inc. The current obv is 1,074,547.

Virpax Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartVirpax Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Virpax Pharmaceuticals Inc. The current mfi is 17.75.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Virpax Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartVirpax Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Virpax Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Virpax Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Virpax Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.983
Ma 20Greater thanMa 503.758
Ma 50Greater thanMa 1003.740
Ma 100Greater thanMa 2003.583
OpenGreater thanClose3.220
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Virpax Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Virpax Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Virpax Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Virpax Pharmaceuticals Inc

I send you an email if I find something interesting about Virpax Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Virpax Pharmaceuticals Inc.

Receive notifications about Virpax Pharmaceuticals Inc in your mailbox!